Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“The reclassification of cannabis hinged on a change in attitude rather than a change in the underlying science.”
UnverifiableConfidence: LOW

Reasoning

The Reason.com article cites a GAO report noting that the DEA's decision to reclassify cannabis reflected a shift in regulatory attitude, not a change in underlying science. This directly supports the claim.

On confidence: The primary source explicitly states that the reclassification of cannabis was driven by a change in attitude rather than new scientific evidence.

Important context

The claim pertains to the rationale behind cannabis's scheduling change under the Controlled Substances Act, emphasizing regulatory interpretation over scientific data.

Evidence

Supporting (1)

  • Tier 1 — Primary source
    Federal drug scheduling relies on vague criteria, GAO report finds

    identical, distinguished only by their intended use. By contrast, cocaine, fentanyl, and methamphetamine are all Schedule II drugs, regardless of whether they are dispensed by pharmacies based on medical prescriptions or purchased on the…

Contextual (3)

  • Tier 1 — Primary source
    Federal drug scheduling relies on vague criteria, GAO report finds

    abuse." But as a recent report from the Government Accountability Office (GAO) notes, the statute does not clearly define either criterion, opening the door to debatable and changeable regulatory judgments with far-reaching criminal…

  • Tier 1 — Primary source
    Federal drug scheduling relies on vague criteria, GAO report finds

    similar to the evidence that the Food and Drug Administration (FDA) demands to approve a drug for prescription use, the DEA's definition essentially equated "accepted medical use" with FDA approval. During the Biden administration, the HHS…

  • Tier 1 — Primary source
    Federal drug scheduling relies on vague criteria, GAO report finds

    cannabis illustrates that puzzle. When Congress enacted the CSA in 1970, it placed marijuana in Schedule I, and the Drug Enforcement Administration (DEA), which had the authority to reclassify drugs in consultation with the Department of…

Limitations

The assessment relies on a single source; additional independent analyses could further corroborate the claim. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.

Last verified:
Oct 1, 2026, 4:49 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

Hazy Drug Classification Criteria Invite Dubious Bureaucratic Judgments

Reason · Jacob Sullum